XPH vs. IBRN
Compare and contrast key facts about SPDR S&P Pharmaceuticals ETF (XPH) and iShares Neuroscience and Healthcare ETF (IBRN).
XPH and IBRN are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. XPH is a passively managed fund by State Street that tracks the performance of the S&P Pharmaceuticals Select Industry Index. It was launched on Jun 19, 2006. IBRN is a passively managed fund by iShares that tracks the performance of the NYSE FactSet Global Neuro Biopharma and MedTech Index. It was launched on Aug 24, 2022. Both XPH and IBRN are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Performance
XPH vs. IBRN - Performance Comparison
Loading graphics...
XPH vs. IBRN - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
XPH SPDR S&P Pharmaceuticals ETF | -3.32% | 31.60% | 4.94% | 2.97% | -4.46% |
IBRN iShares Neuroscience and Healthcare ETF | 1.98% | 28.49% | -2.78% | 0.92% | 5.85% |
Returns By Period
In the year-to-date period, XPH achieves a -3.32% return, which is significantly lower than IBRN's 1.98% return.
XPH
- 1D
- 5.32%
- 1M
- -5.56%
- YTD
- -3.32%
- 6M
- 13.19%
- 1Y
- 24.45%
- 3Y*
- 11.04%
- 5Y*
- 2.79%
- 10Y*
- 3.82%
IBRN
- 1D
- 7.11%
- 1M
- 2.75%
- YTD
- 1.98%
- 6M
- 24.24%
- 1Y
- 48.96%
- 3Y*
- 11.91%
- 5Y*
- —
- 10Y*
- —
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
XPH vs. IBRN - Expense Ratio Comparison
XPH has a 0.35% expense ratio, which is lower than IBRN's 0.47% expense ratio.
Return for Risk
XPH vs. IBRN — Risk / Return Rank
XPH
IBRN
XPH vs. IBRN - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for SPDR S&P Pharmaceuticals ETF (XPH) and iShares Neuroscience and Healthcare ETF (IBRN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| XPH | IBRN | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.00 | 1.68 | -0.67 |
Sortino ratioReturn per unit of downside risk | 1.47 | 2.32 | -0.85 |
Omega ratioGain probability vs. loss probability | 1.19 | 1.29 | -0.10 |
Calmar ratioReturn relative to maximum drawdown | 1.77 | 2.53 | -0.77 |
Martin ratioReturn relative to average drawdown | 5.52 | 9.59 | -4.07 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| XPH | IBRN | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.00 | 1.68 | -0.67 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.14 | — | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.17 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.38 | 0.35 | +0.02 |
Correlation
The correlation between XPH and IBRN is 0.79, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Dividends
XPH vs. IBRN - Dividend Comparison
XPH's dividend yield for the trailing twelve months is around 0.69%, less than IBRN's 0.97% yield.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
XPH SPDR S&P Pharmaceuticals ETF | 0.69% | 0.83% | 1.58% | 1.28% | 1.64% | 0.95% | 0.47% | 0.64% | 0.65% | 0.67% | 0.63% | 7.15% |
IBRN iShares Neuroscience and Healthcare ETF | 0.97% | 0.99% | 0.40% | 0.06% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
XPH vs. IBRN - Drawdown Comparison
The maximum XPH drawdown since its inception was -48.03%, which is greater than IBRN's maximum drawdown of -35.38%. Use the drawdown chart below to compare losses from any high point for XPH and IBRN.
Loading graphics...
Drawdown Indicators
| XPH | IBRN | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -48.03% | -35.38% | -12.65% |
Max Drawdown (1Y)Largest decline over 1 year | -13.15% | -15.44% | +2.29% |
Max Drawdown (5Y)Largest decline over 5 years | -31.63% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -35.97% | — | — |
Current DrawdownCurrent decline from peak | -7.29% | -1.72% | -5.57% |
Average DrawdownAverage peak-to-trough decline | -17.37% | -10.20% | -7.17% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.23% | 4.62% | +0.61% |
Volatility
XPH vs. IBRN - Volatility Comparison
The current volatility for SPDR S&P Pharmaceuticals ETF (XPH) is 9.49%, while iShares Neuroscience and Healthcare ETF (IBRN) has a volatility of 12.31%. This indicates that XPH experiences smaller price fluctuations and is considered to be less risky than IBRN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| XPH | IBRN | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.49% | 12.31% | -2.82% |
Volatility (6M)Calculated over the trailing 6-month period | 16.38% | 19.64% | -3.26% |
Volatility (1Y)Calculated over the trailing 1-year period | 24.72% | 29.56% | -4.84% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 20.56% | 25.40% | -4.84% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.22% | 25.40% | -3.18% |